Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16018 | 1.00 | NR1H2 (0.47) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| SCHEMBL16843 | 1.00 | NR1H2 (0.47) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| Hydrochloric Acid SCHEMBL25337897 | 0.98 | NR1H2 (0.46) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| Piperazine SCHEMBL28853588 | 0.97 | NR1H2 (0.45) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| SCHEMBL28002373 | 0.97 | HPGD (0.48) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| Acetic Acid SCHEMBL28827133 | 0.95 | NR1H2 (0.44) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| Urea SCHEMBL4467391 | 0.95 | NR1H2 (0.44) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| Acetic Acid SCHEMBL28060582 | 0.95 | NR1H2 (0.44) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| SCHEMBL31540 | 0.90 | HPGD (0.48) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| SCHEMBL2898103 | 0.90 | HPGD (0.48) | NR1H2USP2SMN1; SMN2MAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907387-A | Pyrimidopyrrole KRAS inhibitor and preparation method and application thereof | 中山大学 | 2022-08-16 | — | — | CN | claimed |
| CN-114057654-A | Preparation method of (S) -1-Boc-3-methylpiperazine | 苏州艾缇克药物化学有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-111675700-A | Preparation method of novel anti-cancer drug AZD3759 | 通化师范学院 | 2020-09-18 | — | — | CN | claimed |
| CN-111662273-A | Preparation method of tyrosine kinase inhibitor AZD3759 | 通化师范学院 | 2020-09-15 | — | — | CN | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| US-12637458-B2 | Imidazo[1,2-a]pyridine compounds and their use in therapy | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-122070287-A | IRAK 4-targeted degradation agent compound and application thereof | 江苏先声药业有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4041730-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-13 | — | — | EP | disclosed |
| WO-2000000488-A1 | MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 2000-01-06 | — | — | WO | disclosed |
| EP-0938483-A2 | MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5866564-A | STABILITY | SANKYO COMPANY, LIMITED (JP) | 1999-02-02 | — | — | US | disclosed |
| EP-0885888-A1 | ISOQUINOLINE DERIVATIVES AND DRUGS | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1998005292-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE AS MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-12 | — | — | WO | disclosed |
| US-5712267-A | Carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY,. LIMITED (JP) | 1998-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637458-B2 | Imidazo[1,2-a]pyridine compounds and their use in therapy | OGFR, CBR3, CBR1 | NR1H2 242/4885USP2 4064/4885SMN1; SMN2 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.